Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer
Masato Karayama(Ministry of Health Labour and Welfare), Takafumi Suda(Hamamatsu University)
Cited by 44
Related Papers
Evaluation of Programmed Death Ligand 1 (<i>PD-L1</i>) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
|JAMA Network Open|2020|35